YM155 inhibits tumor growth and enhances chemosensitivity to cisplatin in osteosarcoma

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 11, 2015, Pages 2062-2069

  Gao, J Z ^a   Chen, F H ^b   Wang, L ^a   Wei, H ^c   Meng, S L ^c  

^a WEIFANG PEOPLE'S HOSPITAL   (China)

^b Juxian People's Hospital   (China)

^c People's Hospital of Zhangqiu   (China)

Author keywords

Chemosensitivity; Cisplatin; Osteosarcoma

Indexed keywords

CISPLATIN; SEPANTRONIUM BROMIDE; SURVIVIN; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; INHIBITOR OF APOPTOSIS PROTEIN; NAPHTHOQUINONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL VIABILITY; CHEMOSENSITIVITY; CHRONOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; EVIDENCE BASED PRACTICE; FEMALE; HUMAN; HUMAN CELL; MG 63 CELL LINE; MONOTHERAPY; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SW1353 CELL LINE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR XENOGRAFT; U2OS CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE NEOPLASMS; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; TUMOR CELL LINE; TUMOR RECURRENCE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; IMIDAZOLES; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MICE, INBRED ICR; MODELS, ANIMAL; NAPHTHOQUINONES; NEOPLASM RECURRENCE, LOCAL; OSTEOSARCOMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942279858     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. URIBE-BOTERO G, RUSSELL WO, SUTOW WW, MARTIN RG. Primary osteosarcoma of bone. Clinicopathologic investigation of 243 cases, with necropsy studies in 54. Am J Clin Pathol 1977; 67: 427-435.
2. BIELACK SS, CARRLE D, HARDES J, SCHUCK A, PAULUSSEN M. Bone tumors in adolescents and young adults. Curr Treat Options Oncol 2008; 9: 67-80.
3. PROVISOR AJ, ETTINGER LJ, NACHMAN JB, KRAILO MD, MAKLEY JT. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 1997; 15: 76-84.
4. PENNATI M, FOLINI M, ZAFFARONI N. Targeting survivin in cancer therapy. Expert Opin Ther Targets 2008; 12: 463-476.
5. PENNATI M, FOLINI M, ZAFFARONI N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 2007; 28: 1133-1139.
6. SHOENEMAN JK, EHRHART EJ 3RD, EICKHOFF JC, CHARLES JB, POWERS BE, THAMM DH. Expression and function of survivin in canine osteosarcoma. Cancer Res 2012; 72: 249-259.
7. LI F, LING X. Survivin study: an update of "what is the next wave"? J Cell Physiol 2006; 208: 476-486.
8. ZOU J, GAN M, MAO N, ZHU X, SHI Q, YANG H. Sensitization of osteosarcoma cell line SaOS-2 to chemotherapy by downregulatingsurvivin. Arch Med Res 2010; 41: 162-169
9. TSAI HC, HUANG CY, SU HL, TANG CH. CCN2 enhances resistance to cisplatin-mediating cell apoptosis in human osteosarcoma. PLoS One 2014; 9: e90159.
10. WU YF, LIANG XJ, LIU YY, GONG W, LIU JX, WANG XP, ZHUANG ZQ, GUO Y, SHEN HY. Antisense oligonucleotide targeting survivin inhibits growth by inducing apoptosis in human osteosarcoma cells MG-63. Neoplasma 2010; 57: 501-506.
11. ZOU J, GAN M, MAO N, ZHU X, SHI Q, YANG H. Sensitization of osteosarcoma cell line SaOS-2 to chemotherapy by downregulatingsurvivin. Arch Med Res 2010; 41: 162-169.
12. GREVE B, SHEIKH-MOUNESSI F, KEMPER B, ERNST I, GÖTTE M, EICH HT. Survivin, a target to modulate the radiosensitivity of Ewing's sarcoma. Strahlenther Onkol 2012; 188: 1038-1047.
13. MINEMATSU T, IWAI M, SUGIMOTO K, SHIRAI N, NAKAHARA T, USUI T, KAMIMURA H. Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d] imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells. Drug Metab Dispos 2009; 37: 619-628.
14. GIACCONE G, ZATLOUKAL P, ROUBEC J, FLOOR K, MUSIL J, KUTA M, VAN KLAVEREN RJ, CHAUDHARY S, GUNTHER A, SHAMSILI S. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, nonsmall-cell lung cancer. J Clin Oncol 2009; 27: 4481-4486.
15. LIANG H, ZHANG L, XU R, JU XL. Silencing of survivin using YM155 induces apoptosis and chemosensitization in neuroblastomas cells. Eur Rev Med Pharmacol Sci 2013; 17: 2909-2915.
16. YAMANAKA K, NAKAHARA T, YAMAUCHI T, KITA A, TAKEUCHI M, KIYONAGA F, KANEKO N, SASAMATA M. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. Clin Cancer Res 2011; 17: 5423-5431.
17. LEWIS KD, SAMLOWSKI W, WARD J, CATLETT J, CRANMER L, KIRKWOOD J, LAWSON D, WHITMAN E, GONZALEZ R. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs 2011; 29: 161-166.
18. KITA A, NAKAHARA T, YAMANAKA K, NAKANO K, NAKATA M, MORI M, KANEKO N, KOUTOKU H, IZUMISAWA N, SASAMATA M. Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. Leuk Res 2011; 35: 787-792.
19. YOON DH, SHIN JS, JIN DH, HONG SW, JUNG KA, KIM SM, HONG YS, KIM KP, LEE JL, SUH C, LEE JS, KIM TW. The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2. Anticancer Res 2012; 32: 1681-1688.
20. NAKAHARA T, KITA A, YAMANAKA K, MORI M, AMINO N, TAKEUCHI M, TOMINAGA F, HATAKEYAMA S, KINOYAMA I, MATSUHISA A, KUDOH M, SASAMATA M.YM155, a nov el small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007; 67: 8014-8021.
21. YAMANAKA K, NAKATA M, KANEKO N, FUSHIKI H, KITA A, NAKAHARA T, KOUTOKU H, SASAMATA M.YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer. Int J Oncol 2011; 39: 569-575.
22. TAO YF, LU J, DU XJ, SUN LC, ZHAO X, PENG L, CAO L, XIAO PF, PANG L, WU D, WANG N, FENG X, LI YH, NI J, WANG J, PAN J. Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells. BMC Cancer 2012; 12: 619.
23. BERGMAN PJ. Mechanisms of anticancer drug resistance. Vet Clin North Am Small Anim Pract 2003; 33: 651-667.
24. CHOU AJ, GORLICK R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 2006; 6: 1075-1085.
25. WALTERS DK, STEINMANN P, LANGSAM B, SCHMUTZ S, BORN W, FUCHS B. Identification of potential chemoresistance genes in osteosarcoma. Anticancer Res 2008; 28: 673-679.
26. SUN PL, JIN Y, KIM H, SEO AN, JHEON S, LEE CT, CHUNG JH. Survivin expression is an independent poor prognostic marker in lung adenocarcinoma but not in squamous cell carcinoma. Virchows Arch 2013; 463: 427-436.
27. ZHANG LQ, WANG J, JIANG F, XU L, LIU FY, YIN R. Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis. PLoS One 2012; 7: e34100.
28. CHU XY, CHEN LB, WANG JH, SU QS, YANG JR, LIN Y, XUE LJ, LIU XB, MO XB. Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer. J Surg Oncol 2012; 105: 520-528.
29. BASTA-JOVANOVIC G, RADOJEVIC-SKODRIC S, BRASANAC D, DJURICIC S, MILASIN J, BOGDANOVIC L, OPRIC D, SAVIN M, BARALIC I, JOVANOVIC M. Prognostic value of survivin expression in Wilms tumor. J BUON 2012; 17: 168-173.
30. ZHENG WE, CHEN H, YUAN SF, WU LL, ZHANG W, SUN HY, CHEN WJ. Overexpression of βIII-tubulin and survivin associated with drug resistance to docetaxel-based chemotherapy in advanced gastric cancer. J BUON 2012; 17: 284-290.
31. KARAMI H, BARADARAN B, ESFAHANI A, ESTIAR MA, NAGHAVI-BEHZAD M, SAKHINIA M, SAKHINIA E. siRNAmediated silencing of survivin inhibits proliferation and enhances etoposide chemosensitivity in acute myeloid leukemia cells. Asian Pac J Cancer Prev 2013; 14: 7719-7724.